Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | KDM1A | O60341 | 2/20 | 0.48 |
| ▸ | FNTA | P49354 | 2/20 | 0.44 |
| ▸ | FNTB | P49356 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD1 | P21728 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4061572 | 0.85 | PRCP (0.59) | PRCPLMNAKDM1ARECQLHTR2A | |
| SCHEMBL29561967 | 0.85 | PRCP (0.59) | PRCPLMNAKDM1ARECQLHTR2A | |
| SCHEMBL22784268 | 0.85 | PRCP (0.59) | PRCPLMNAKDM1ARECQLHTR2A | |
| SCHEMBL4062159 | 0.84 | PRCP (0.47) | PRCPLMNAKDM1ARECQLDRD2 | |
| SCHEMBL3956419 | 0.81 | KDM1A (0.51) | PRCPKDM1AFNTAFNTBRECQL | |
| SCHEMBL4064540 | 0.81 | KDM1A (0.51) | PRCPKDM1AFNTAFNTBRECQL | |
| SCHEMBL3956423 | 0.81 | KDM1A (0.51) | PRCPKDM1AFNTAFNTBRECQL | |
| SCHEMBL30973226 | 0.74 | PRCP (1.00) | PRCPKDM1ARECQLDRD2DRD1 | |
| SCHEMBL21063715 | 0.74 | PRCP (1.00) | PRCPKDM1ARECQLDRD2DRD1 | |
| SCHEMBL3072702 | 0.74 | PRCP (1.00) | PRCPKDM1ARECQLDRD2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3724188-B1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3724188-B1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20210163471-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS | 2021-06-03 | — | — | US | disclosed |
| US-20210163471-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS | 2021-06-03 | — | — | US | disclosed |
| EP-3724188-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | Arkuda Therapeutics (US) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019118528-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2019-06-20 | — | — | WO | disclosed |
| WO-2019118528-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163471-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | GRN, PRNP, PSEN1 | PRCP 66/4885LMNA 1957/4885KDM1A 4422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.